Aditxt, Inc.

As of October 5, 2023, Aditxt, Inc. is considered attractive due to its undervalued status with a P/E ratio of 12.5, a P/B ratio of 1.2, and a manageable D/E ratio of 0.5, outperforming peers and the Sensex.

As of October 1, 2023, there is insufficient technical data for Aditxt, Inc. to determine a bullish or bearish outlook.

As of March 2022, Aditxt, Inc.'s management team includes Amro Albanna (Chairman, President, CEO), Shahrokh Shabahang (Chief Innovation Officer, Director), and five Independent Directors: Laura Anthony, Brian Brady, Namvar Kiaie, and Dr. Jeffrey Runge. They oversee the company's strategic direction and operations.

Aditxt, Inc. is a pre-clinical life sciences company focused on immune system health through reprogramming and monitoring technologies. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of $2.97 million and reported a net loss of $6 million for Q1 2025.

As of Jun 18, Aditxt, Inc. has a market capitalization of 2.97 million, with net sales of 0.05 million and a net profit of -26.10 million over the last four quarters. The company reported shareholder's funds of 8.87 million and total assets of 32.54 million as of Dec 24.